LONDON – Azeria Therapeutics Ltd. has raised £32 million (US$41.3 million) in a series B round to take forward small-molecule inhibitors of FOXA1, a transcription factor that is pivotal to the growth and progression of estrogen receptor (ER)-positive breast cancer.
Even though November’s full moon had come and gone more than a week previous, Werewolf Therapeutics Inc. came out of the shadows Wednesday with a $56 million series A fundraiser to state its plans to develop immune-stimulatory therapeutics to trigger immune responses to cancer.
HONG KONG – SK Holdings Co. Ltd. invested KRW10 billion (US$8.6 million) in Standigm Inc., an artificial intelligence (AI)-powered biotech company based in Seoul, Korea. It is the second big investment Standigm has attracted this year after a KRW13 billion series B round in March.
HONG KONG U.S.-based biotech firm Egenesis Inc., headquartered in Cambridge, Mass., has received $100 million through a series B funding round for the development of safe and effective human-compatible organs through gene editing.